Text Size

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Laker, Henry Ford Health System
ClinicalTrials.gov Identifier:
NCT01683955
First received: September 8, 2012
Last updated: NA
Last verified: September 2012
History: No changes posted
  Purpose

This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.


Condition Intervention Phase
Acute Blood Loss Anemia
Osteoarthritis, Hip
 Drug: Transexamic Acid
Drug: Placebo
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Henry Ford Health System:

Primary Outcome Measures:
  • postoperative blood loss [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days ] [ Designated as safety issue: Yes ]
    Preoperative and lowest postoperative hemoglobin


Secondary Outcome Measures:
  • postoperative transfusion rate [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days ] [ Designated as safety issue: Yes ]
    number of units transfused postoperatively


Enrollment: 101
Study Start Date: June 2011
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tranexamic Acid
Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
 Drug: Transexamic Acid
Topical tranexamic acid (2g/100mL 0.9% saline)
Other Name: cyclokapron
Placebo Comparator: Placebo
100mL 0.9% NS, applied topically
 Drug: Placebo
100mL 0.9% sterile saline
Other Name: placebo

Detailed Description:

Autologous (donor) blood transfusion is an expensive and common occurrence after total hip replacement. There have been many proposed adjunctive measures to decrease intraoperative and postoperative blood loss during such surgery. Most of these include thrombin inhibition, so-called "minimally- invasive" techniques or instrumentation, or other adjunctive drugs. Hitherto, tranexamic acid, a specific drug that promotes part of the clotting cascade, has been used extensively in multiple areas of surgery with multiple studies evaluating its efficacy in cardiac surgery, spinal procedures, and as a dental swishing solution after tooth extraction. There have been small studies evaluating intravenous tranexamic acid and its effect on total hip replacements, with some promising results. The topical form of TA has been evaluated in only one prospective, randomized clinical trial with a significant decrease in postoperative blood loss and a trend towards decreased autologous blood transfusion rates. This study proposes to further evaluate tranexamic acid as an inexpensive and viable option for use in total hip arthroplasty. The topical form of the drug has been shown to achieve these hemostatic effects without increasing the risk of blood clots after surgery. A rigorous analysis of the effects of tranexamic acid demand a more standardized approach. Such a regimen is practiced at Henry Ford Hospital as all patients on the Adult Reconstruction service are placed on an identical dose of enoxaparin (a subcutaneous blood thinner) postoperatively for two weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All adult patients over age eighteen
  • Primary unilateral total hip arthroplasty at Henry Ford Hospital (Detroit, Michigan, United States) and Henry Ford West Bloomfield Hospital (West Bloomfield, Michigan, United States)

Exclusion Criteria:

  • patient history of venous thromboembolic disease or coagulopathy
  • use of anticoagulant medications within 7 days of surgery
  • history of arterial embolic disease
  • history of Class III or IV heart failure
  • renal failure
  • intraoperative cardiovascular, pulmonary, orthopaedic, or anesthetic complication (MI, intraoperative fracture, vasopressor support, emergent intubation).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01683955

Locations
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48067
Sponsors and Collaborators
Henry Ford Health System
Investigators
Principal Investigator: Michael Laker, M.D. Henry Ford Health Systems
  More Information

No publications provided

Responsible Party: Michael Laker, Principal Investigator, Henry Ford Health System
ClinicalTrials.gov Identifier: NCT01683955     History of Changes
Other Study ID Numbers: TEAHIPS
Study First Received: September 8, 2012
Last Updated: September 8, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Henry Ford Health System:
Tranexamic Acid
Blood transfusion
Total hip arthroplasty

Additional relevant MeSH terms:
Anemia
Hemorrhage
Osteoarthritis
Osteoarthritis, Hip
Anemia, Hypochromic
Hematologic Diseases
Pathologic Processes
Arthritis
Joint Diseases
Musculoskeletal Diseases
 Rheumatic Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 19, 2013